Two recent developments from the DOJ on corporate fraud issues signal that the agency won’t be stepping off the gas when it comes to investigating health-care fraud matters, according to industry attorneys.
The first is the Department of Justice’s intervention in a fraud lawsuit against UnitedHealth Group on Feb. 16. The DOJ’s taking the reins in this case is the latest warning to Medicare Advantage insurers that their practices are being scrutinized for possible wrongdoing (United States ex rel. Poehling v. UnitedHealth Grp., C.D. Cal., No. 16-cv-8697, unsealed 2/16/17).
Tim McCormack, a partner with Constantine Cannon LLP in Washington representing whistle-blower Benjamin Poehling, said the intervention in the False Claims Act lawsuit is a signal that the DOJ is looking at this area, and this particular type of fraud, closely.
Stradling Yocca Carlson & Rauth PC shareholder Jason de Bretteville, who leads the firm’s white-collar criminal defense practice, told Bloomberg BNA Feb. 17 the DOJ’s civil division “significantly expanded FCA enforcement in the healthcare industry under [the] Obama [administration],” including against upcoding practices, and the DOJ’s action appears to continue the trend.
The second indication of the DOJ’s intentions regarding fraud came in the form of corporate compliance guidance released Feb. 8 by the agency’s Criminal Division (without an accompanying press release or other announcement). The under-the-radar guidance nevertheless provided health-care fraud attorneys with a detailed view of how the agency evaluates corporate compliance programs in fraud investigations, providing much-needed practical guidance for the industry, attorneys told me.
The guidance, titled Evaluation of Corporate Compliance Programs, consists of a series of questions federal prosecutors “may ask in making an individualized determination” of how to judge a corporation’s compliance efforts in a fraud investigation.
Melissa L. Jampol, with Epstein Becker & Green, saw a connection between the timing of the guidance and the confirmation of Jeff Sessions as attorney general Feb. 8. Jampol, a New York member in the firm’s life sciences practice, told Bloomberg BNA Feb. 22 the guidance’s release signals the DOJ’s intention to continue its current course of pursuing health-care fraud, especially in light of the monetary return generated from health-care fraud enforcement and the growing share of the economy devoted to health care.
Jampol also noted that certain portions of the guidance borrow ideas from federal sentencing guidelines for organizations (rather than individual persons) as well. Jampol pointed out that “the two factors that mitigate the ultimate punishment of an organization [criminally],” a defendant’s maintaining of an effective compliance program and self-reporting wrongdoing, cooperation with investigations and acceptance of responsibility, appear in the DOJ guidance as well.
Read more about the UnitedHealth litigation in my story here.
Read more about the DOJ’s new compliance guidance here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)